Drug intelligence / Profile preview

Honghua Ruyi Pills

Development stage
Phase 4
Lead developer
奇正藏药
Administration
Oral
01

Overview

Honghua Ruyi Pills (HHRYW), also known as 'Safflower Wishful Pill' or 'Guge Sangpei' in Tibetan, is a traditional Tibetan medicine oral formulation developed and marketed by Tibet Cheezheng Tibetan Medicine (Gansu Cheezheng). The formulation is a modification of the classical '25-ingredient Podophyllum Pill' and contains 25 key ingredients, most of which are native to the Qinghai-Tibet Plateau. It is an approved traditional herbal medicine primarily indicated for various gynecological conditions, including endometriosis-associated dysmenorrhea, pelvic inflammatory disease pain, and menstruation disorders. The drug demonstrates anti-inflammatory and analgesic properties, effectively alleviating chills and pain associated with menstrual irregularities. While its clinical efficacy is documented, its specific molecular targets and pharmacological mechanisms have not been fully characterized in Western pharmacological terms.

Brand names
Honghua Ruyi Pills
Other names
Safflower Wishful PillGuge Sangpei红花如意丸
02

Targets

PRLR (Prolactin receptor)TNFA (Tumor necrosis factor alpha (soluble))ESR1 (ERα)

Beyond the preview

Go deeper on Honghua Ruyi Pills.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Honghua Ruyi Pills.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call